Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by World Health Organization (2016).~* Should have failed at least 1 line of prior therapy (defined as failure to respond to therapy, and/or progression during or after therapy).~* Should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.~* Should have adequate hematologic, kidney and liver function as described in the protocol.~* For participants enrolling into the Expansion Cohort only: a documented FMS-like Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in the protocol.~Exclusion Criteria:~* Has a diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.~* Has a history of other malignancies within 2 years prior to study entry, with exceptions as described in the protocol.~* Has active central nervous system leukemia.~* Has a history of chronic New York Heart Association (NYHA) class IV heart failure.~* Has a corrected QT interval of \> 450 ms.~* Has a chronic respiratory disease that requires continuous oxygen use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation Venetoclax + Gilteritinib (Type: EXPERIMENTAL): Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
- Dose Expansion Venetoclax + Gilteritinib (Type: EXPERIMENTAL): Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.

Based on this trial design, predict the completion outcome and termination type (if applicable).